“Pharmaceutical companies are important resources for our country. Italy is among the first places in Europe for the production of drugs but we must push more on research and innovation ”. This was stated by Angela Ianaro, member of the Social Affairs Commission of the Chamber of Deputies and president of the “Science and Health” Intergroup speaking at the “Digital Health” webinar. Innovation in the treatment of chronic autoimmune rheumatological and dermatological diseases ”, promoted by Ucb Italia. During the meeting it emerged that the future that awaits us foresees the digitalization of healthcare, as a necessary act to improve people’s lives, where the problem is not so much technological but organizational, of sharing processes with operators, of safe infrastructures and stable. But the interaction between public and private is necessary.
“Certainly the dialogue between all the actors of the health system, therefore between patient associations, scientific societies, institutions and the productive world is fundamental – added Ianaro -. With Covid we learned how important a healthy interaction between public and private was, in terms of vaccines, how research and innovation conducted in small companies and financed with public money was then amplified in terms of production and availability thanks to to the efforts of pharmaceutical companies “.
On the post-Covid NHS, Ianaro has no doubts: “We cannot be convinced that after Covid the modern National Health Service cannot ignore digital healthcare and this is closely linked to a reorganization of territorial healthcare. This reorganization must start from technological assumptions and all the actors involved have a fundamental role, even the pharmaceutical companies for their skills and know-how will play an increasingly important role “.